Molecular Characterization of Imported and Autochthonous Dengue in Northeastern Spain
Jessica Navero‐Castillejos(Barcelona Institute for Global Health), Miguel J. Martínez, Teresa Falgueras(Badalona Serveis Assistencials), Elena Sulleiro(Instituto de Salud Carlos III), Núria Torner(Centro de Investigación Biomédica en Red), José Muñóz(Hospital Clínic de Barcelona), Josep Barrachina(Hospital Clínic de Barcelona), Carmina Martí(Hospital General de Granollers), Rosa Albarracín(Hospital Clínic de Barcelona), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Ana Vázquez(Instituto de Salud Carlos III), Jaume Llaberia(Agència de Qualitat i Avaluació Sanitàries de Catalunya), Mireia Jané(Generalitat de Catalunya), Anna Vilamala(Hospital Universitari de Vic), Aida Peiró-Mestres(Departament de Salut), Verónica Gonzalo(Hospital Clínic de Barcelona), Virginia Plasencia, Aroa Silgado(Vall d'Hebron Hospital Universitari), María Paz Sánchez‐Seco(Instituto de Salud Carlos III), María Ángeles Pulido(Hospital General de Granollers), Daniel Camprubí(Barcelona Institute for Global Health), Mireia Navarro(Hospital Clínic de Barcelona), Alexander Navarro(Hospital Clínic de Barcelona), Josefa Martínez Pérez, María Luisa Navarro, Ana Calderón(Badalona Serveis Assistencials), Miguel Micó(Althaia), Montserrat Roldán(Hospital Clínic de Barcelona), Rosa Rubio, Rosa Benitez(Hospital Universitari Germans Trias i Pujol), Izaskun Alejo-Cancho(Hospital Clínic de Barcelona)
Cited by 30
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334